Small-Cell Lung Cancer: MRI Monitoring Shows Cognitive

What did the MAVERICK lung cancer trial find?

Results presented at the World Conference on Lung Cancer compared two approaches after initial treatment for small-cell lung cancer: scheduled brain MRI alone or the same scans combined with prophylactic cranial irradiation, known as PCI. Participants had limited-stage or extensive-stage disease and no brain metastases on their enrollment MRI. The randomized phase III study therefore addressed a preventive treatment decision. [IASLC trial announcement](https://www.iaslc.org/iaslc-news/press-release/phase-iii-maverick-trial-supports-brain-mri-surveillance-alone-standard).

The cognitive outcome combined two events: deterioration on standardized cognitive testing or death. SWOG reported a hazard ratio of 0.60 favoring MRI alone. This measures a relative difference over follow-up; it does not mean that 40% of participants avoided dementia. Cognitive testing can detect changes that do not meet the clinical definition of dementia. [SWOG results](https://www.swog.org/news-events/news/2026/09/14/brain-mri-surveillance-without-prophylactic-cranial-irradiation).

Why is preventive brain radiation used in small-cell lung cancer?

Small-cell lung cancer grows quickly and can spread early. The National Cancer Institute describes brain radiation as one treatment used to lower the risk of cancer spreading to the brain. This preventive use differs from radiation directed at brain metastases already identified during assessment. The distinction matters because someone with established brain metastases faces a different treatment decision from the patients entering MAVERICK. [NCI treatment overview](https://www.cancer.gov/types/lung/patient/small-cell-lung-treatment-pdq).

Studies conducted before routine MRI helped establish PCI by showing fewer brain metastases and improved survival. Modern scanning raises a new question: can clinicians monitor the brain closely and treat metastases when detected while avoiding radiation exposure for some patients? MAVERICK strengthens that argument. IASLC also reported fewer severe treatment-related adverse events with MRI alone, although surveillance does not itself prevent cancer from reaching the brain. [IASLC findings and background](https://www.iaslc.org/iaslc-news/press-release/phase-iii-maverick-trial-supports-brain-mri-surveillance-alone-standard).

Should patients choose MRI monitoring instead of preventive radiation?

The preliminary overall survival comparison included 128 deaths; the final analysis is planned after 190. No apparent difference at this stage does not establish that the approaches provide equivalent long-term survival. The results are conference findings, and the completed analysis will be important when assessing the balance between preserving cognition and controlling cancer. [SWOG survival analysis](https://www.swog.org/news-events/news/2026/09/14/brain-mri-surveillance-without-prophylactic-cranial-irradiation).

Surveillance also requires an organized follow-up plan. MAVERICK scheduled scans throughout two years, and its protocol recommended radiation treatment if brain metastases developed. A practical implication is that patients considering this approach need dependable access to MRI, timely review of results and a clear treatment pathway if a scan detects cancer. The findings do not support simply omitting PCI and abandoning brain monitoring. Patients can ask their oncology team how closely their situation matches the trial population. [MAVERICK study protocol overview](https://www.swog.org/media/10102).